LIVIVO - Search results -

Search results

Result 1 - 10 of total 66

Search options

Article ; Online: Gut microbiome as a novel cardiovascular therapeutic target.

Singh, Vishal / Yeoh, Beng San / Vijay-Kumar, Matam

2016 Volume 27, Page(s) 8–12

Abstract: ... on our current knowledge on gut microbiota in modulating CVD, how gut microbiota can be therapeutically exploited ... with intra-intestinal and extra-intestinal diseases including risk factors of cardiovascular disease (CVD ... the cardiovascular risk factors. Accordingly, in this review we summarized the potential strategies, based ...

Abstract	Over the last two decades, our understanding of gut microbiotal composition and its association with intra-intestinal and extra-intestinal diseases including risk factors of cardiovascular disease (CVD) namely metabolic syndrome and atherosclerosis, have been increased exponentially. A pertinent question which often arises in researchers' community is on how to manipulate the gut microbial ecology to 'cure' the cardiovascular risk factors. Accordingly, in this review we summarized the potential strategies, based on our current knowledge on gut microbiota in modulating CVD, how gut microbiota can be therapeutically exploited by targeting their metabolic activity to alleviate the risk factors of CVD.
MeSH term(s)	Animals ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/metabolism ; Cardiovascular Diseases/microbiology ; Gastrointestinal Microbiome/drug effects ; Gastrointestinal Microbiome/physiology ; Humans ; Intestines/microbiology ; Risk Factors
Language	English
Publishing date	2016-04
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2037057-X
ISSN	1471-4973 ; 1471-4892
ISSN (online)	1471-4973
ISSN	1471-4892
DOI	10.1016/j.coph.2016.01.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5608: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Targeting the Gut Microbiome to Treat Cardiometabolic Disease.

Theofilis, Panagiotis / Vlachakis, Panayotis K / Oikonomou, Evangelos / Tsioufis, Konstantinos / Tousoulis, Dimitris

Current atherosclerosis reports

2024 Volume 26, Issue 2, Page(s) 25–34

Abstract: ... inflammation, and cardiovascular function. Furthermore, a growing corpus of research is available on microbiome ... cardiovascular diseases, constitute a worldwide health crisis of unparalleled proportions. The human gut microbiota has ... and clinical practice. The gut microbiome is a beacon of hope for improving the management ...

Abstract	Purpose of review: Cardiometabolic diseases, which include obesity, type 2 diabetes, and cardiovascular diseases, constitute a worldwide health crisis of unparalleled proportions. The human gut microbiota has emerged as a prominent topic of inquiry in the search for novel treatment techniques. This review summarizes current research on the potential of addressing the gut microbiota to treat cardiometabolic disease. Recent findings: Recent studies have highlighted a complex link between the gut microbiota and host physiology, shedding light on the several processes through which gut microorganisms impact metabolic health, inflammation, and cardiovascular function. Furthermore, a growing corpus of research is available on microbiome-based therapies such as dietary interventions, probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. These therapies show promise as methods for reshaping the gut microbiota and, as a result, improving cardiometabolic outcomes. However, hurdles remain, ranging from the intricacies of microbiome research to the necessity for tailored treatments that take individual microbial variations into consideration, emphasizing the significance of furthering research to bridge the gap between microbiome science and clinical practice. The gut microbiome is a beacon of hope for improving the management of cardiometabolic disease in the age of precision medicine, since its association with their pathophysiology is constantly being unraveled and strengthened. Available studies point to the potential of gut microbiome-based therapeutics, which remains to be tested in appropriately designed clinical trials. Further preclinical research is, however, essential to provide answers to the existing obstacles, with the ultimate goal of enhancing patient care.
MeSH term(s)	Humans ; Gastrointestinal Microbiome/physiology ; Diabetes Mellitus, Type 2/therapy ; Prebiotics ; Probiotics/therapeutic use ; Cardiovascular Diseases/therapy
Chemical Substances	Prebiotics
Language	English
Publishing date	2024-01-05
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057369-8
ISSN	1534-6242 ; 1523-3804
ISSN (online)	1534-6242
ISSN	1523-3804
DOI	10.1007/s11883-023-01183-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5534: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Alterations in the gut mycobiome with coronary artery disease severity.

An, Kun / Jia, Yanxiong / Xie, Boqia / Gao, Jie / Chen, Yihang / Yuan, Wen / Zhong, Jiuchang / Su, Pixiong / Liu, Xiaoyan

EBioMedicine

2024 Volume 103, Page(s) 105137

Abstract: ... highlights the potential role of gut fungi in CAD and may facilitate the development of novel biomarkers and ... were closely linked to gut microbiome dysbiosis in patients with CAD. Furthermore, disease classifiers ... therapeutic targets for CAD.: Funding: This work was supported by the grants from the National ...

Abstract	Background: Coronary artery disease (CAD) is a prevalent cardiovascular condition, and numerous studies have linked gut bacterial imbalance to CAD. However, the relationship of gut fungi, another essential component of the intestinal microbiota, with CAD remains poorly understood. Methods: In this cross-sectional study, we analyzed fecal samples from 132 participants, split into 31 healthy controls and 101 CAD patients, further categorized into stable CAD (38), unstable angina (41), and acute myocardial infarction (22) groups. We conducted internal transcribed spacer 1 (ITS1) and 16S sequencing to examine gut fungal and bacterial communities. Findings: Based on ITS1 analyses, Ascomycota and Basidiomycota were the dominant fungal phyla in all the groups. The α diversity of gut mycobiome remained unaltered among the control group and CAD subgroups; however, the structure and composition of the mycobiota differed significantly with the progression of CAD. The abundances of 15 taxa gradually changed with the occurrence and progression of the disease and were significantly correlated with major CAD risk factor indicators. The mycobiome changes were closely linked to gut microbiome dysbiosis in patients with CAD. Furthermore, disease classifiers based on gut fungi effectively identified subgroups with different degrees of CAD. Finally, the FUNGuild analysis further categorized these fungi into distinct ecological guilds. Interpretation: In conclusion, the structure and composition of the gut fungal community differed from healthy controls to various subtypes of CAD, revealing key fungi taxa alterations linked to the onset and progression of CAD. Our study highlights the potential role of gut fungi in CAD and may facilitate the development of novel biomarkers and therapeutic targets for CAD. Funding: This work was supported by the grants from the National Natural Science Foundation of China (No. 82170302, 92168117, 82370432), National clinical key specialty construction project- Cardiovascular Surgery, the Reform and Development Program of Beijing Institute of Respiratory Medicine (No. Ggyfz202417, Ggyfz202308), the Beijing Natural Science Foundation (No. 7222068); and the Clinical Research Incubation Program of Beijing Chaoyang Hospital Affiliated to Capital Medical University (No. CYFH202209).
MeSH term(s)	Humans ; Gastrointestinal Microbiome ; Coronary Artery Disease/microbiology ; Male ; Female ; Middle Aged ; Mycobiome ; Aged ; Cross-Sectional Studies ; Feces/microbiology ; Metagenomics/methods ; Fungi/genetics ; Fungi/classification ; Fungi/isolation & purification ; Severity of Illness Index ; Dysbiosis/microbiology ; Case-Control Studies ; RNA, Ribosomal, 16S/genetics ; Adult
Language	English
Publishing date	2024-05-03
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2851331-9
ISSN	2352-3964
ISSN (online)	2352-3964
DOI	10.1016/j.ebiom.2024.105137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7090: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The gut microbiome across the cardiovascular risk spectrum.

Prins, Femke M / Collij, Valerie / Groot, Hilde E / Björk, Johannes R / Swarte, J Casper / Andreu-Sánchez, Sergio / Jansen, Bernadien H / Fu, Jingyuan / Harmsen, Hermie J M / Zhernakova, Alexandra / Lipsic, Erik / van der Harst, Pim / Weersma, Rinse K / Gacesa, Ranko

European journal of preventive cardiology

2023 Volume 31, Issue 8, Page(s) 935–944

Abstract: ... worldwide. Identifying new targets is crucial for enhancing preventive and therapeutic strategies. The gut ... metabolic pathways that were differently abundant among the groups. In the gut microbiome of STEMI patients, there ... therapeutic targets. ...

Abstract	Aims: Despite treatment advancements, cardiovascular disease remains a leading cause of death worldwide. Identifying new targets is crucial for enhancing preventive and therapeutic strategies. The gut microbiome has been associated with coronary artery disease (CAD), however our understanding of specific changes during CAD development remains limited. We aimed to investigate microbiome changes in participants without clinically manifest CAD with different cardiovascular risk levels and in patients with ST-elevation myocardial infarction (STEMI). Methods and results: In this cross-sectional study, we characterized the gut microbiome using metagenomics of 411 faecal samples from individuals with low (n = 130), intermediate (n = 130), and high (n = 125) cardiovascular risk based on the Framingham score, and STEMI patients (n = 26). We analysed diversity, and differential abundance of species and functional pathways while accounting for confounders including medication and technical covariates. Collinsella stercoris, Flavonifractor plautii, and Ruthenibacterium lactatiformans showed increased abundances with cardiovascular risk, while Streptococcus thermophilus was negatively associated. Differential abundance analysis revealed eight species and 49 predicted metabolic pathways that were differently abundant among the groups. In the gut microbiome of STEMI patients, there was a depletion of pathways linked to vitamin, lipid, and amino acid biosynthesis. Conclusion: We identified four microbial species showing a gradual trend in abundance from low-risk individuals to those with STEMI, and observed differential abundant species and pathways in STEMI patients compared to those without clinically manifest CAD. Further investigation is warranted to gain deeper understanding of their precise role in CAD progression and potential implications, with the ultimate goal of identifying novel therapeutic targets.
MeSH term(s)	Humans ; Gastrointestinal Microbiome ; Cross-Sectional Studies ; Male ; Female ; Middle Aged ; Feces/microbiology ; Heart Disease Risk Factors ; Risk Assessment ; Aged ; Bacteria/isolation & purification ; Bacteria/classification ; Bacteria/genetics ; ST Elevation Myocardial Infarction/microbiology ; Metagenomics ; Cardiovascular Diseases/microbiology ; Cardiovascular Diseases/epidemiology ; Dysbiosis ; Adult
Language	English
Publishing date	2023-12-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2626011-6
ISSN	2047-4881 ; 2047-4873
ISSN (online)	2047-4881
ISSN	2047-4873
DOI	10.1093/eurjpc/zwad377
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4686: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation.

Shi, Bozhong / Li, Haoyu / He, Xiaomin

Gut microbes

2024 Volume 16, Issue 1, Page(s) 2323237

Abstract: ... machine learning to target gut microbiota for developing diagnosis system and screening for new therapeutic ... The gut microbiome is known as the tenth system of the human body that plays a vital role ... achievements of targeting gut microbiota in CVDs prevention, diagnosis and treatment. Personalized strategies ...

Abstract	The gut microbiome is known as the tenth system of the human body that plays a vital role in the intersection between health and disease. The considerable inter-individual variability in gut microbiota poses both challenges and great prospects in promoting precision medicine in cardiovascular diseases (CVDs). In this review, based on the development, evolution, and influencing factors of gut microbiota in a full life circle, we summarized the recent advances on the characteristic alteration in gut microbiota in CVDs throughout different life stages, and depicted their pathological links in mechanism, as well as the highlight achievements of targeting gut microbiota in CVDs prevention, diagnosis and treatment. Personalized strategies could be tailored according to gut microbiota characteristics in different life stages, including gut microbiota-blood metabolites combined prediction and diagnosis, dietary interventions, lifestyle improvements, probiotic or prebiotic supplements. However, to fulfill the promise of a lifelong cardiovascular health, more mechanism studies should progress from correlation to causality and decipher novel mechanisms linking specific microbes and CVDs. It is also promising to use the burgeoning artificial intelligence and machine learning to target gut microbiota for developing diagnosis system and screening for new therapeutic interventions.
MeSH term(s)	Humans ; Precision Medicine ; Cardiovascular Diseases/therapy ; Gastrointestinal Microbiome ; Artificial Intelligence ; Dietary Supplements
Language	English
Publishing date	2024-02-27
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2575755-6
ISSN	1949-0984 ; 1949-0984
ISSN (online)	1949-0984
ISSN	1949-0984
DOI	10.1080/19490976.2024.2323237
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cardiovascular diseases and the heart-gut cross talk.

Majumder, Snehali / Kiritkumar Makwana, Rohan / Shetty, Varun / Mukherjee, Suparna / Narayan, Pradeep

Indian heart journal

2023 Volume 76, Issue 2, Page(s) 94–100

Abstract: ... the gastrointestinal tract may lead to the development of novel therapeutic targets and therapies for the prevention and ... bidirectional connection between the heart and the gut, we shed light on novel future options for the prevention ... on heart-gut cross talk and its implications for cardiovascular disease. To uncover relevant preclinical ...

Abstract	The purpose of this narrative review is to provide a comprehensive overview of current research on heart-gut cross talk and its implications for cardiovascular disease. To uncover relevant preclinical and clinical research examining heart-gut cross talk, a thorough literature search was undertaken utilising electronic databases. The chosen publications were critically examined, and major findings were synthesised to offer a thorough perspective on the subject. We want to synthesise the most recent study findings, explain the underlying mechanisms, and provide potential treatment techniques. By exploring bidirectional connection between the heart and the gut, we shed light on novel future options for the prevention and treatment of cardiovascular diseases. The heart-gut cross talk is an exciting field of study with implications for cardiovascular disease. Understanding the complex connection between the heart and the gastrointestinal tract may lead to the development of novel therapeutic targets and therapies for the prevention and management of cardiovascular diseases. Future research should concentrate on identifying the specific processes driving this crosstalk as well as assessing the efficacy of therapies targeting the gut microbiota and the gut-brain axis in improving cardiovascular outcomes.
MeSH term(s)	Humans ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/physiopathology ; Cardiovascular Diseases/therapy ; Gastrointestinal Microbiome/physiology ; Gastrointestinal Tract/physiopathology ; Gastrointestinal Tract/physiology
Language	English
Publishing date	2023-12-07
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	604366-5
ISSN	2213-3763 ; 0019-4832
ISSN (online)	2213-3763
ISSN	0019-4832
DOI	10.1016/j.ihj.2023.12.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 616: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Berberine promotes the degradation of phenylacetic acid to prevent thrombosis by modulating gut microbiota.

Zhang, Hao-Jian / Fu, Jie / Yu, Hang / Xu, Hui / Hu, Jia-Chun / Lu, Jin-Yue / Bu, Meng-Meng / Zhai, Zhao / Wang, Jing-Yue / Ye, Meng-Liang / Zuo, Heng-Tong / Song, Jian-Ye / Zhao, Yi / Jiang, Jian-Dong / Wang, Yan

Phytomedicine : international journal of phytotherapy and phytopharmacology

2024 Volume 128, Page(s) 155517

Abstract: ... as a novel target for preventing thrombosis, with a focus on berberine, a natural compound known ... alkaloid. While berberine's cardiovascular benefits are well-documented, its impact on thrombosis remains ... for its effectiveness in managing cardiovascular conditions.: Methods: Intraperitoneal injection of carrageenan ...

Abstract	Background: Berberine is the main bioactive constituent of Coptis chinensis, a quaternary ammonium alkaloid. While berberine's cardiovascular benefits are well-documented, its impact on thrombosis remains not fully understood. Purpose: This study investigates the potential of intestinal microbiota as a novel target for preventing thrombosis, with a focus on berberine, a natural compound known for its effectiveness in managing cardiovascular conditions. Methods: Intraperitoneal injection of carrageenan induces the secretion of chemical mediators such as histamine and serotonin from mast cells to promote thrombosis. This model can directly and visually observe the progression of thrombosis in a time-dependent manner. Thrombosis was induced by intravenous injection of 1 % carrageenan solution (20 mg/kg) to all mice except the vehicle control group. Quantitative analysis of gut microbiota metabolites through LC/MS. Then, the gut microbiota of mice was analyzed using 16S rRNA sequencing to assess the changes. Finally, the effects of gut microbiota on thrombosis were explored by fecal microbiota transplantation. Results: Our research shows that berberine inhibits thrombosis by altering intestinal microbiota composition and related metabolites. Notably, berberine curtails the biosynthesis of phenylacetylglycine, a thrombosis-promoting coproduct of the host-intestinal microbiota, by promoting phenylacetic acid degradation. This research underscores the significance of phenylacetylglycine as a thrombosis-promoting risk factor, as evidenced by the ability of intraperitoneal phenylacetylglycine injection to reverse berberine's efficacy. Fecal microbiota transplantation experiment confirms the crucial role of intestinal microbiota in thrombus formation. Conclusion: Initiating our investigation from the perspective of the gut microbiota, we have, for the first time, unveiled that berberine inhibits thrombus formation by promoting the degradation of phenylacetic acid, consequently suppressing the biosynthesis of PAG. This discovery further substantiates the intricate interplay between the gut microbiota and thrombosis. Our study advances the understanding that intestinal microbiota plays a crucial role in thrombosis development and highlights berberine-mediated intestinal microbiota modulation as a promising therapeutic approach for thrombosis prevention.
MeSH term(s)	Animals ; Gastrointestinal Microbiome/drug effects ; Berberine/pharmacology ; Berberine/analogs & derivatives ; Thrombosis/prevention & control ; Male ; Mice ; Phenylacetates/pharmacology ; Carrageenan ; Coptis/chemistry ; Disease Models, Animal ; Mice, Inbred C57BL ; Fecal Microbiota Transplantation ; RNA, Ribosomal, 16S
Chemical Substances	Berberine (0I8Y3P32UF) ; Phenylacetates ; phenylacetic acid (ER5I1W795A) ; Carrageenan (9000-07-1) ; RNA, Ribosomal, 16S
Language	English
Publishing date	2024-03-07
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1205240-1
ISSN	1618-095X ; 0944-7113
ISSN (online)	1618-095X
ISSN	0944-7113
DOI	10.1016/j.phymed.2024.155517
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4115: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The Role of Gut Microbiota and the Potential Effects of Probiotics in Heart Failure.

Petruzziello, Carmine / Saviano, Angela / Manetti, Luca Luigi / Macerola, Noemi / Ojetti, Veronica

Medicina (Kaunas, Lithuania)

2024 Volume 60, Issue 2

Abstract: ... physiology, and environmental factors. Among these factors, the gut microbiota has emerged as a novel and ... Additionally, we explore the potential of using probiotics as a therapeutic strategy to modulate the gut ... signals, and microbial products exert profound effects on cardiovascular health. This review aims ...

Abstract	Heart failure (HF) remains a significant global health challenge, affecting millions of individuals worldwide and posing a substantial burden on healthcare systems. HF is a syndrome of intricate pathophysiology, involving systemic inflammation, oxidative stress, metabolic perturbations, and maladaptive structural changes in the heart. It is influenced by complex interactions between cardiac function, systemic physiology, and environmental factors. Among these factors, the gut microbiota has emerged as a novel and intriguing player in the landscape of HF pathophysiology. The gut microbiota, beyond its role in digestion and nutrient absorption, impacts immune responses, metabolic processes, and, as suggested by evidence in the literature, the development and progression of HF. There is a bidirectional communication between the gut and the heart, often known as the gut-heart axis, through which gut microbiota-derived metabolites, immune signals, and microbial products exert profound effects on cardiovascular health. This review aims to provide a comprehensive overview of the intricate relationship between the gut microbiota and HF. Additionally, we explore the potential of using probiotics as a therapeutic strategy to modulate the gut microbiota's composition and attenuate the adverse effects observed in HF. Conventional therapeutic approaches targeting hemodynamic and neurohormonal dysregulation have substantially improved the management of HF, but emerging research is exploring the potential implications of harnessing the gut microbiota for innovative approaches in HF treatment.
MeSH term(s)	Humans ; Gastrointestinal Microbiome/physiology ; Heart Failure/therapy ; Heart ; Probiotics/therapeutic use ; Inflammation
Language	English
Publishing date	2024-02-04
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2188113-3
ISSN	1648-9144 ; 1010-660X
ISSN (online)	1648-9144
ISSN	1010-660X
DOI	10.3390/medicina60020271
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6270: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Role of Biological Sex in the Cardiovascular-Gut Microbiome Axis.

Li, Shuangyue / Kararigas, Georgios

Frontiers in cardiovascular medicine

2022 Volume 8, Page(s) 759735

Abstract: ... disease. Technological advances have dramatically expanded our knowledge of the gut microbiome. Increasing ... evidence has indicated a strong link between gut microbiota and the development of cardiovascular ... progression of CVD. We further discuss how the gut microbiome may differ between the sexes and how it may be ...

Abstract	There has been a recent, unprecedented interest in the role of gut microbiota in host health and disease. Technological advances have dramatically expanded our knowledge of the gut microbiome. Increasing evidence has indicated a strong link between gut microbiota and the development of cardiovascular diseases (CVD). In the present article, we discuss the contribution of gut microbiota in the development and progression of CVD. We further discuss how the gut microbiome may differ between the sexes and how it may be influenced by sex hormones. We put forward that regulation of microbial composition and function by sex might lead to sex-biased disease susceptibility, thereby offering a mechanistic insight into sex differences in CVD. A better understanding of this could identify novel targets, ultimately contributing to the development of innovative preventive, diagnostic and therapeutic strategies for men and women.
Language	English
Publishing date	2022-01-10
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2021.759735
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Gut microbiota in sarcopenia and heart failure.

Liu, Chia-Feng / Tang, W H Wilson

The journal of cardiovascular aging

2022 Volume 2, Issue 3

Abstract: ... mechanistic and clinical insights into developing novel therapeutic strategies that target these GMM pathways ... diseases and aging. This review will examine the emerging evidence for the influence of the gut microbiome ... we have limited insights into who would benefit. Mechanistic links between gut microbial metabolites (GMM ...

Abstract	Sarcopenia is common in aging and in patients with heart failure (HF) who may experience worse outcomes. Patients with muscle wasting are more likely to experience falls and can have serious complications when undergoing cardiac procedures. While intensive nutritional support and exercise rehabilitation can help reverse some of these changes, they are often under-prescribed in a timely manner, and we have limited insights into who would benefit. Mechanistic links between gut microbial metabolites (GMM) have been identified and may contribute to adverse clinical outcomes in patients with cardio-renal diseases and aging. This review will examine the emerging evidence for the influence of the gut microbiome-derived metabolites and notable signaling pathways involved in both sarcopenia and HF, especially those linked to dietary intake and mitochondrial metabolism. This provides a unique opportunity to gain mechanistic and clinical insights into developing novel therapeutic strategies that target these GMM pathways or through tailored nutritional modulation to prevent progressive muscle wasting in elderly patients with heart failure.
Language	English
Publishing date	2022-07-05
Publishing country	United States
Document type	Journal Article
ISSN	2768-5993
ISSN (online)	2768-5993
DOI	10.20517/jca.2022.07
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED